Morgan Stanley Maintains a Buy on Haleon plc (HLN) With a PT of $10.95

Haleon plc (NYSE:HLN) is one of the best NYSE stocks to buy under $20. In a report released on August 4, Morgan Stanley maintained a Buy rating on Haleon plc (NYSE:HLN) with a price target of $10.95.

Why Haleon Plc (HLN) Surged On Monday?

A pharmacist and a customer discussing a novel therapeutic oral health product in a pharmacy.

Haleon plc (NYSE:HLN) reported unaudited results for H1 2025 on June 30, reporting notable growth in EMEA & LatAm and Asia-Pacific, while showing continued outperformance in Oral Health.

Management reported organic revenue growth across EMEA & LatAm (+5.2%) and Asia-Pacific (+5.0%), partially offsetting a 0.4% decline in North America. The trends reflected a weak US consumer and retail environment.

The company also reported that 58% of businesses gained or maintained market share, suggesting the resilience of its brand portfolio. Free cash flow for the first half of the year reached £734 million, up £184 million year-on-year, primarily due to progress on working capital initiatives.

Haleon plc (NYSE:HLN) provides personal healthcare products, with a focus on consumer healthcare. The company’s operations are divided into the following geographical segments: North America, EMEA and LatAm, and Asia Pacific.

While we acknowledge the potential of HLN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than HLN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.